ArticleFrontiers in immunology2022
Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge.The Journal of clinical investigation · 2023Trial
- ConvexGating infers gating strategies from clusters in single cell cytometry data.Nature communications · 2026Article
- Immune cell dynamics, cytokines, and extracellular vesicles in systemic inflammatory response syndrome (SIRS): a multiparametric analysis.Journal of translational medicine · 2025Article
- Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity.Human vaccines & immunotherapeutics · 2023Review
- Carriers of the p.P522R variant in PLCγ2 have a slightly more responsive immune system.Molecular neurodegeneration · 2023Article
- Performance of spectral flow cytometry and mass cytometry for the study of innate myeloid cell populations.Frontiers in immunology · 2023Article
- Automated EuroFlow approach for standardized in-depth dissection of human circulating B-cells and plasma cells.Frontiers in immunology · 2023Article
- In-depth blood immune profiling of Good syndrome patients.Frontiers in immunology · 2023Article
- Monitoring of the Forgotten Immune System during Critical Illness-A Narrative Review.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innate myeloid cell (IMC) populations form an essential part of innate immunity. Flow cytometric (FCM) monitoring of IMCs in peripheral blood (PB) has great clinical potential for disease monitoring due to their role in maintenance of tissue homeostasis and ability to sense micro-environmental changes, such as inflammatory processes and tissue damage. However, the lack of standardized and validated approaches has hampered broad clinical implementation. For accurate identification and separation of IMC populations, 62 antibodies against 44 different proteins were evaluated. In multiple rounds of EuroFlow-based design-testing-evaluation-redesign, finally 16 antibodies were selected for their non-redundancy and separation power. Accordingly, two antibody combinations were designed for fast, sensitive, and reproducible FCM monitoring of IMC populations in PB in clinical settings (11-color; 13 antibodies) and translational research (14-color; 16 antibodies). Performance of pre-analytical and analytical variables among different instruments, together with optimized post-analytical data analysis and reference values were assessed. Overall, 265 blood samples were used for design and validation of the antibody combinations and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.